Processing

Please wait...

Settings

Settings

Goto Application

1. WO2008022505 - USE OF RUBESCENSINE A AND DERIVATIVES THEREOF IN PHARMACY

Publication Number WO/2008/022505
Publication Date 28.02.2008
International Application No. PCT/CN2007/000380
International Filing Date 05.02.2007
IPC
A61K 31/52 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
A61K 31/70 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
A61K 38/19 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
A61K 31/202 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
20having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
202having three or more double bonds, e.g. linolenic acid
A61P 35/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/202
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
20having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
202having three or more double bonds, e.g. linolenic
A61K 31/52
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
A61K 31/70
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
Applicants
  • 上海交通大学医学院附属瑞金医院 RUI JIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE [CN]/[CN] (AllExceptUS)
  • 陈竺 CHEN, Zhu [CN]/[CN] (UsOnly)
  • 陈赛娟 CHEN, Saijuan [CN]/[CN] (UsOnly)
  • 王振义 WANG, Zhenyi [CN]/[CN] (UsOnly)
  • 周光飚 ZHOU, Guangbiao [CN]/[CN] (UsOnly)
Inventors
  • 陈竺 CHEN, Zhu
  • 陈赛娟 CHEN, Saijuan
  • 王振义 WANG, Zhenyi
  • 周光飚 ZHOU, Guangbiao
Agents
  • 上海翼胜专利事务所 ESSEN PATENT AGENCY (SHANGHAI)
Priority Data
200610030200.718.08.2006CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) USE OF RUBESCENSINE A AND DERIVATIVES THEREOF IN PHARMACY
(FR) UTILISATION DE RUBESCENSINE A ET DE SES DÉRIVÉS EN PHARMACIE
(ZH) 冬凌草甲素及其衍生物在制药中的应用
Abstract
(EN)
Use of rubescensine A and derivatives thereof in pharmacy. Rubescensine A can induce the apoptosis of leukemic cells in vitro, and can prolong the survival period of mouse model of t(8;21) leukemia in vivo or delay the growth of tumor in body. Sequential, joint application of rubescensine A and chemotherapeutics, such as cytarabine or agents for inducing differentiation may be more effective in prolonging the survival period of mouse of t(8;21) leukemia.
(FR)
L'invention concerne l'utilisation de rubescensine A et de ses dérivés en pharmacie. La rubescensine A peut induire l'apoptose des cellules leucémiques in vitro, et peut prolonger la période de survie d'un modèle de souris leucémique t(8;21) in vivo, ou retarder la croissance d'une tumeur dans le corps. L'application séquentielle, conjointe, de rubescensine A et d'agents chimiothérapeutiques, tels que la cytarabine, ou d'agents induisant la différentiation, peut être plus efficace dans le prolongement de la période de survie de souris atteintes de leucémie t(8;21).
Also published as
Latest bibliographic data on file with the International Bureau